Mesoblast Stock Leads 3 Australian Growth Shares With Strong Earnings Expectations
Euro area manufacturing just recorded its strongest expansion in four years, helped by inventory rebuilding, defense projects, and heavy data center investment. That mix points to companies that can turn solid demand into stronger earnings. Healthy high growth potential stocks that analysts already expect to grow earnings and that sit on sound balance sheets look especially interesting. This article highlights three standouts from that screener worth a closer look.
The three stocks below are just a starting sample, with the full screen surfacing 91 more companies with similarly strong growth profiles and financial footing that are not covered here. If you want to go straight to the source, use the Healthy high growth potential screener to identify, filter, and analyze the ideas that best match your own conviction.
Mesoblast (ASX:MSB)
Overview: Mesoblast is a Melbourne based biotech that develops regenerative medicine using mesenchymal lineage cells, with lead product Remestemcel L and other MPC based therapies in late stage trials for severe inflammatory and cardiovascular diseases such as steroid refractory acute graft versus host disease, inflammatory bowel disease, chronic heart failure and chronic low back pain. These programs sit at the center of its link to the Healthy high growth potential theme because they target large, high need conditions where successful approvals could turn its current pipeline into a meaningful earnings engine.
Operations: Mesoblast currently generates about US$65 million from the development and commercialization of its cell technology platform.
Market Cap: A$3.1 billion
Mesoblast provides exposure to late stage cell therapies that analysts expect to translate into strong earnings growth over the next few years, backed by an acceptable financial position and recent funding that supports ongoing trials and commercialization. Ryoncil already has an FDA approval in pediatric steroid refractory acute GvHD and is being pushed into larger adult and inflammatory indications. Rexlemestrocel L is in a pivotal Phase 3 trial for chronic low back pain with RMAT designation and top line data due in 2027. The catch is that Mesoblast is still loss making and relies heavily on external borrowing, so setbacks in trials or reimbursement could affect both earnings and funding options. Investors who understand that trade off between high growth potential and clinical or regulatory risk may find the story worth following more closely.
Mesoblast’s late stage pipeline could be the kind of growth story many investors feel they are missing. Yet the real question is how those trials might shape future earnings. Before making up your mind, review the analyst forecasts for Mesoblast and see what the current expectations might be overlooking.
Build your own high growth shortlist around Mesoblast style opportunities
Mesoblast and the two other stocks in this article all came from a single screen, but the real value comes when you shape the filters yourself. Use our flexible Screener to mix growth, quality, valuation and risk checks to suit your approach, or start with one of our curated Investing Ideas for ready made shortlists.
Westgold Resources (ASX:WGX)
Overview: Westgold Resources is a Perth based gold producer that explores, develops, and operates gold mines across the Murchison and Southern Goldfields regions in Western Australia. These operating hubs and surrounding exploration ground form its clearest link to the Healthy high growth potential screener, as they underpin analysts’ expectations for earnings growth on top of an acceptable financial position.
Operations: Westgold Resources generates about A$1.3 billion of revenue from Murchison and A$690 million from Southern Goldfields, all from within Australia.
Market Cap: A$5.9 billion
Westgold Resources gives you direct exposure to Western Australian gold production. The heavy lifting for earnings growth comes from its Murchison and Southern Goldfields mines, backed by a large reserve and resource base at assets like Beta Hunt and the new Fletcher zone. Analysts expect strong earnings growth over the next few years, helped by higher volumes, improving grades and recent upgrades at hubs such as Cue and Higginsville, all supported by a debt free balance sheet and significant liquidity. The flip side is real. Lower grade ore, rising costs, integration risk from the Karora deal and slower adoption of new technology could pressure margins if conditions turn. For investors focused on growth tied to real producing assets, that mix of upside and operational risk is worth a closer look.
Westgold Resources has accelerating production plans tied to a debt free balance sheet, yet the full earnings swing is not fully priced in. Read the analyst forecasts for Westgold Resources to see what the market might be missing next.
Lynas Rare Earths (ASX:LYC)
Overview: Lynas Rare Earths is an integrated rare earths miner and processor that takes ore from its Mt Weld mine in Western Australia and turns it into high value oxides and metals like neodymium and praseodymium at its Kalgoorlie and Gebeng plants for use in electric vehicles and wind turbines. The company also produces a broader mix of light and heavy rare earth products and runs associated processing and corporate operations in Australia and Malaysia.
Operations: Lynas Rare Earths currently generates about A$716 million in revenue from its Rare Earth Operations segment.
Market Cap: A$16.3 billion
Lynas Rare Earths provides direct exposure to one of the few large scale, non Chinese sources of rare earth materials that feed EV motors and wind turbines. This positioning is what places it in the Healthy high growth potential screener. Analysts have published expectations for earnings and revenue outcomes as Mt Weld, Kalgoorlie and Gebeng ramp. Some fair value estimates are above the current share price, so the market is effectively asking investors to judge whether the company’s growth path and margin trajectory are realistic. At the same time, heavy capital needs, reliance on external funding and regulatory risk in Malaysia mean that execution missteps or weaker demand could challenge that thesis. For investors willing to weigh those trade offs, Lynas represents a higher risk, higher impact growth story that may warrant closer attention around upcoming 2026 results.
Lynas Rare Earths sits at the intersection of scarce supply and rising EV and turbine demand, yet the real story is how earnings could evolve from here. Scan the analyst forecasts for Lynas Rare Earths to see what the current forecasts might be missing.
Seeking Fresh Alternatives Before Momentum Flies
Market leadership can shift fast, and early breakouts often move before most investors react. Use these fresh stock shortlists while they are still under the radar for now, act now.
- Spot established payout engines before yields get compressed by late buyers and review the 6 dividend fortresses curated for income focused portfolios.
- Catch potential beneficiaries of electrification and infrastructure upgrades while they are still quietly building momentum across the 9 top copper producer stocks.
- Zero in on producers that could benefit if bullion regains momentum and scan the curated 32 elite gold producer stocks before these opportunities get fully crowded.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com